Incyte (INCY) Enterprise Value (2010 - 2026)
Incyte's (INCY) quarterly Enterprise Value came in at -$4.5 billion in Q2 2026, down 87.29% YoY from -$35.7 billion in Q2 2025, and down 12.95% on a QoQ basis from -$4.0 billion in Q1 2026.
Incyte (INCY) Enterprise Value (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Enterprise Value data on file, last reported at -$4.5 billion in Q2 2026.
- Quarterly Enterprise Value fell 87.29% year-over-year to -$4.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$4.5 billion (down 87.29% YoY) and the FY2025 annual result came in at -$3.6 billion, down 65.92% from the prior year.
- Enterprise Value fell to -$4.5 billion in Q2 2026, from -$4.0 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.4 billion in Q2 2024 to a low of -$4.5 billion in Q2 2026.
- A 5-year average of -$3.0 billion and a median of -$3.0 billion in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 57.66% — and 2026, when it tumbled 87.29%.
- Tracing INCY's Enterprise Value over 5 years: stood at -$3.2 billion in 2022, then declined by 12.88% to -$3.7 billion in 2023, then soared by 40.97% to -$2.2 billion in 2024, then slumped by 65.92% to -$3.6 billion in 2025, then declined by 26.68% to -$4.5 billion in 2026.
- The last three Enterprise Value figures came in at -$4.5 billion (Q2 2026), -$4.0 billion (Q1 2026), and -$3.6 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | -4.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.54 Bn |
| Mar 31, 2026 | -4.02 Bn |
| Dec 31, 2025 | -3.58 Bn |
| Sep 30, 2025 | -2.93 Bn |
| Jun 30, 2025 | -2.42 Bn |
| Mar 31, 2025 | -2.41 Bn |
| Dec 31, 2024 | -2.16 Bn |
| Sep 30, 2024 | -1.77 Bn |
| Jun 30, 2024 | -1.45 Bn |
| Mar 31, 2024 | -3.85 Bn |
| Dec 31, 2023 | -3.66 Bn |
| Sep 30, 2023 | -3.52 Bn |
| Jun 30, 2023 | -3.42 Bn |
| Mar 31, 2023 | -3.11 Bn |
| Dec 31, 2022 | -3.24 Bn |
| Sep 30, 2022 | -2.98 Bn |
| Jun 30, 2022 | -2.72 Bn |
| Mar 31, 2022 | -2.54 Bn |
| Dec 31, 2021 | -2.35 Bn |
| Sep 30, 2021 | -2.28 Bn |